A method of analyzing genetic polymorphisms that predispose to cancer and individual sensitivities to pharmaceuticals using oligonucleotide biological microchip (biochip)

摘要

1. a set of u043fu0440u0430u0439u043cu0435u0440u043eu0432 u0434u043bu00a0 express analysis of genetic polymorphism, sequence identified in the list of sequences (SEQ id no: 1 - 44).;2. a set of u043eu043bu0438u0433u043eu043du0443u043au043bu0435u043eu0442u0438u0434u043eu0432 u0434u043bu00a0 express analysis of genetic polymorphism, sequence identified in the list of sequences (SEQ id no: 45 to 72).;3. biochip u0434u043bu00a0 express analysis of genetic polymorphism, u043fu0440u0435u0434u0441u0442u0430u0432u043bu00a0u044eu0449u0438u0439 a substrate with a u0438u043cu043cu043eu0431u0438u043bu0438u0437u043eu0432u0430u043du043du044bu0445 on her u043eu043bu0438u0433u043eu043du0443u043au043bu0435u043eu0442u0438u0434u043eu0432 described in 2.;4. a way to express analysis of genetic polymorphism u0434u043bu00a0 u043eu043fu0440u0435u0434u0435u043bu0435u043du0438u00a0 u0444u0430u0440u043cu0430u043au043eu0433u0435u043du0435u0442u0438u0447u0435u0441u043au043eu0433u043e status rights and u0432u044bu00a0u0432u043bu0435u043du0438u00a0 genetic predisposition to u043eu043du043au043eu043b u043eu0433u0438u0447u0435u0441u043au0438u043c u0437u0430u0431u043eu043bu0435u0432u0430u043du0438u00a0u043c, including verification u043fu043eu043bu0438u043cu043eu0440u0444u043du044bu0445 options in the clinical sample dna sequence with the following stages:;(a) u043cu0443u043bu044cu0442u0438u043fu043bu0435u043au0441u043du0430u00a0 "u0433u043du0435u0437u0434u043eu0432u0430u00a0" u0434u0432u0443u0445u044du0442u0430u043fu043du0430u00a0 u043fu043eu043bu0438u043cu0435u0440u0430u0437u043du0430u00a0 u0446u0435u043fu043du0430u00a0 u0440u0435u0430u043au0446u0438u00a0 (pcr) using a set of u043fu0440u0430u0439u043cu0435u0440u043eu0432 outlined in paragraph 1, u0434u043bu00a0 u0430u043cu043fu043bu0438u0444u0438u043au0430u0446u0438u0438 fragment s dna and u043cu0435u0447u0435u043du0438u00a0 pcr - product for the second stage pcr.;(b) ensuring u0431u0438u043eu0447u0438u043fu0430 described in paragraph 3, containing a set of u0438u043cu043cu043eu0431u0438u043bu0438u0437u043eu0432u0430u043du043du044bu0445 u043eu043bu0438u0433u043eu043du0443u043au043bu0435u043eu0442u0438u0434u043eu0432 described in clause 2, u0434u043bu00a0 u043fu0440u043eu0432u0435u0434u0435u043du0438u00a0 hybridization;;(b) u0433u0438u0431u0440u0438u0434u0438u0437u0430u0446u0438u00a0 u0430u043cu043fu043bu0438u0444u0438u0446u0438u0440u043eu0432u0430u043du043du043eu0433u043e the scarred product to u0431u0438u043eu0447u0438u043fu0435;;(g) u0440u0435u0433u0438u0441u0442u0440u0430u0446u0438u00a0 and u0438u043du0442u0435u0440u043fu0440u0435u0442u0430u0446u0438u00a0 hybridization results.;5. method for 1, in which the stage (a) for the second stage pcr fragment u0434u043bu00a0 fluorescent u043cu0435u0447u0435u043du0438u00a0 gene using fluorescent marked by 5 '- end of the u043fu0440u0430u0439u043cu0435u0440u044b.;6. method for 2, which in the stage (b) u0434u043bu00a0 u043eu0431u0435u0441u043fu0435u0447u0435u043du0438u00a0 u0431u0438u043eu0447u0438u043fu0430 described in paragraph 3, containing a set of u0438u043cu043cu043eu0431u0438u043bu0438u0437u043eu0432u0430u043du043du044bu0445 u043eu043bu0438u0433u043eu043du0443u043au043bu0435u043eu0442u0438u0434u043eu0432, as outlined in the 2, use the method of u0444u043eu0442u043eu0438u043du0434u0443u0446u0438u0440u0443u0435u043cu043eu0439 u0441u043eu043fu043eu043bu0438u043cu0435u0440u0438u0437u0430u0446u0438u0438 in u0430u043au0440u0438u043bu0430u043cu0438u0434u043du043eu043c gehle.;7. method for article 3, in which the (in) use u0443u0441u043bu043eu0432u0438u00a0 hybridization, that provide a high degree of differentiation between perfect and imperfect u0433u0438u0431u0440u0438u0434u0438u0437 u0430u0446u0438u043eu043du043du044bu043cu0438 u0434u0443u043fu043bu0435u043au0441u0430u043cu0438.;8. method for paragraph 4, in which the registration results of hybridization under (g) u043fu0440u043eu0432u043eu0434u00a0u0442 using a portable analyzer u0431u0438u043eu0447u0438u043fu043eu0432, supplied with the electric charge coupled device camera.;9. method for paragraph 4, in which the registration results of hybridization under (g) supplied with the electric u043fu0440u043eu0432u043eu0434u00a0u0442 by fluorescent microscope, a ccd camera.;10. method for paragraph 4, in which the interpretation of the results for the (g) u043fu0440u043eu0432u043eu0434u00a0u0442 visually.;11. method for paragraph 4, in which the interpretation of the results for the (g) u043fu0440u043eu0432u043eu0434u00a0u0442 using the automated analysis of u0438u0437u043eu0431u0440u0430u0436u0435u043du0438u00a0.;12. method for paragraph 4, in which u0438u043du0442u0435u0440u043fu0440u0435u0442u0438u0440u043eu0432u0430u043du043du044bu0435 results using u0434u043bu00a0 purposes of medical diagnosis, u043eu043fu0440u0435u0434u0435u043bu0435u043du0438u00a0 predisposition to various u0437u0430u0431u043eu043bu0435u0432u0430u043du0438u00a0u043c and correction of doses of drugs.